Skip to content
Screener

Supernus Pharmaceuticals SUPN Other — Total revenues

Other product segments

Qelbree
$77.84M+20.2%
GOCOVRI
$35.24M+14.8%
Royalty, licensing, and other revenues
$29.31M+274%
Collaboration revenue (ZURZUVAE)
$27.64M
Trokendi XR
$9.48M-26.0%
ONAPGO
$8.38M
APOKYN
$7.73M-48.4%
Oxtellar XR
$7.42M-27.2%

Similar metrics at other companies

Asset Entities logo
ASSTOther revenue — Total revenues
$43K+514%
FTAI Aviation Ltd. logo
FTAIOther revenue — Total revenues
$6.21M+19,923%
FIP
FIPOther revenue — Total revenues
$1.13M+112,900%
Red Robin Gourmet Burgers logo
RRGBOther revenue — Total revenues
$2.23M+8.5%
Kinetik Holdings logo
KNTKOther revenue — Total revenues
$3.97M+40.2%
Agilon Health logo
AGLOther operating revenue — Total revenues
$1.82M-38.1%

Other financials

Income statement

See full
Revenue$207.7M+38.6%
Gross profit$184.3M+37.5%
Operating income-$8.3M+18.8%
Net income-$2.3M+80.6%
EPS (diluted)-$0.04+81.0%

Balance sheet

See full
Cash & equivalents$186.3M+60.8%
Total debt$40.9M+26.6%
Total equity$1.1B+4.5%
Total assets$1.5B+11.4%

Cash flow

See full
Operating cash flow$66.5M+117%
CapEx--100%
Free cash flow$66.5M+120%

Valuation

See full
Market cap$2.72B+14.3%
Enterprise value$2.57B+13.6%
P/S3.5×-0.1×

Profitability

See full
Gross margin89.4%+1.0pp
Operating margin-7.8%-18.9pp
Net margin-3.7%-13.0pp
FCF margin27.9%+3.4pp

Returns & leverage

See full
Return on equity-2.8%-9.1pp
Debt / equity0.0×
Current ratio-0.5×

Where this comes from

Reported directly by Supernus Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:15 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001356576-26-000022
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
ONAPGO8,375
APOKYN7,72814,976
Oxtellar XR7,42210,198
Other(1)4,6668,579
Total net product sales150,753141,988
Collaboration revenue (ZURZUVAE)(2)27,643
Royalty, licensing, and other revenues29,3097,836
Total revenues$207,705$149,824

Item 1. Unaudited Condensed Consolidated Financial Statements

FAQ

What is Supernus Pharmaceuticals's other — total revenues?
Supernus Pharmaceuticals (SUPN) reported other — total revenues of $4.67M in Q1 2026.
How has Supernus Pharmaceuticals's other — total revenues changed year-over-year?
Supernus Pharmaceuticals's other — total revenues decreased by 45.6% year-over-year, from $8.58M to $4.67M.
What is the long-term trend for Supernus Pharmaceuticals's other — total revenues?
Over 4 years (2021 to 2025), Supernus Pharmaceuticals's other — total revenues has grown at a -5.0% compound annual growth rate (CAGR), from $33.09M to $26.91M.
What does other — total revenues mean?
This metric represents the total gross revenue generated by the company's non-core or miscellaneous business segments that fall outside of its primary therapeutic focus areas. It captures the financial contribution of ancillary products or services that do not constitute the main revenue drivers for the organization. Monitoring this figure helps investors assess the performance and stability of secondary revenue streams within the broader corporate portfolio.

Ask your AI about Supernus Pharmaceuticals's other — total revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude